With their newest lab, the team Irving-based Caris Life Sciences hopes to make cancer diagnosis more accurate, convenient, and detailed than ever before. The $45 million liquid biopsy facility in ...

Caris Life Sciences, Inc. is rated a Hold with positive EBITDA & free cash flow driven by strong MI segment performance. Read ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

IRVING, Texas, April 25, 2022 /PRNewswire/ -- Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to ...

An Irving-based molecular science firm has agreed to pay $2.8 million to settle a claim that it delayed molecular tests for breast cancer patients in order to receive a higher payout from Medicare.

Irving-based Caris Life Sciences' new Phoenix liquid biopsy lab enables the company to further develop and launch its blood-based cancer test called Caris Assure, according to the company.